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A
	 Is	red-yeast	rice	a	safe	and		
effective	alternative	to	statins?	
	 	 Yes,	 but	 perhaps	 not	 the	 red-
	 	 yeast	 rice	 extracts	 available	 in	 the	
United	States.	
In	 patients	 with	 known	 coronary	 ar-
tery	disease	 and	dyslipidemia	 (secondary	
prevention),	 therapy	 with	 red-yeast	 rice	
extract	containing	naturally-occurring	lov-
astatin	is	associated	with	a	30%	reduction	
in	 coronary	 heart	 disease	 (CHD)	mortal-
ity	and	a	60%	reduction	in	myocardial	 in-
farction	(MI),	similar	to	the	effect	of	statin	
medications	(strength	of	recommendation	
[SOR]:	 B,	 randomized	 controlled	 trials	
[RCTs]	in	China).	
In	 patients	 older	 than	 65	 years	 with	
hypertension	and	a	previous	MI,	the	rate	of	
adverse	 effects	 from	 lovastatin-containing	
red-yeast	rice	is	2.1%	(SOR:	B,	RCT	in	China).	
In	patients	with	previous	statin	 intol-
erance,	the	rates	of	myalgias	and	treatment	
discontinuation	with	lovastatin-containing	
red-yeast	rice	therapy	are	similar	to	either	
placebo	 or	 another	 statin	 (SOR:	 C,	 low-
powered	RCTs).	
The	US	Food	and	Drug	Administration	
(FDA)	doesn’t	allow	lovastatin-containing	
red-yeast	rice	products	on	the	US	market;	
physicians	should	be	aware	 that	products	
purchased	by	patients	online	contain	vari-
able	amounts	of	lovastatin.
Evidence summary
Red-yeast	 rice	 is	 a	Chinese	dietary	 and	me-
dicinal	product	of	yeast	(Monascus purpure-
us)	grown	on	rice.	It	contains	a	wide	range	of	
biologically	active	compounds,	including	lo-
vastatin	(monacolin	K).	The	FDA	has	banned	
the	sale	of	red-yeast	rice	products	with	more	
than	trace	amounts	of	lovastatin.1	
Red-yeast rice beats placebo,  
similar to statins 
A	 systematic	 review	 of	 22	 RCTs	 (N=6520),	
primarily	 conducted	 in	 China	 using	 600	 to	
2400	 mg	 red-yeast	 rice	 extract	 daily	 (lovas-
tatin	content	5-20	mg),	assessed	outcomes	in	
patients	with	known	CHD	and	dyslipidemia.2	
In	 one	 trial	 of	 4870	 patients,	 users	 of	 red-
yeast	rice	had	significant	reductions	in	CHD	
mortality	(relative	risk	[RR]=0.69;	95%	confi-
dence	 interval	 [CI],	 0.54-0.89),	 incidence	 of	
MI	(RR=0.39;	95%	CI,	0.28-0.55),	and	revascu-
larization	(RR=0.67;	95%	CI,	0.50-0.89)	com-
pared	with	placebo	users.	
However,	 when	 compared	 with	 statin	
therapy,	red-yeast	rice	didn’t	yield	statistically	
significant	differences	in	CHD	mortality	(2	tri-
als,	N=220;	RR=0.26;	95%	CI,	0.06-1.21),	inci-
dence	of	MI	 (1	 trial,	N=84;	RR=0.95;	95%	CI,	
0.30-3.05)	or	 revascularization	(1	 trial,	N=84;	
RR=1.14;	95%	CI,	0.38-3.46).
Red-yeast rice outperforms placebo  
in CHD and MI—but not stroke 
A	 secondary	 analysis	 of	 an	 RCT	 evaluated	
the	impact	of	red-yeast	rice	extract	(600	mg	
twice	a	day)	 for	4.5	years	on	cardiovascular	
events	 and	 mortality	 in	 1530	 Chinese	 pa-
tients	 60	 years	 of	 age	 and	older	with	hyper-
tension	 and	 a	 previous	 MI.3	 The	 lovastatin	
content	of	the	red-yeast	rice	was	5	to	6.4	mg/d.
Compared	 with	 placebo,	 red-yeast	 rice	
was	 associated	 with	 a	 lower	 incidence	 of	
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CHD	 events	 (RR=0.63;	 95%	 CI,	 0.36-0.83),	
nonfatal	MI	(RR=0.48;	95%	CI,	0.37-0.71),	and	
all-cause	 mortality	 (RR=0.65;	 95%	 CI,	 0.49-
0.83)	 but	 not	 with	 a	 statistically	 significant	
difference	 in	 stroke	 (RR=0.63;	 95%	CI,	 0.47-
1.09)	 or	 cardiac	 revascularization	 (RR=0.68;	
95%	CI,	0.52-1.19).	
Total	 adverse	 events	 in	 this	 study	 were	
similar	 for	 red-yeast	 rice	 and	placebo	 (2.1%	
vs	 1.2%,	 respectively;	P>.05).	They	 included	
gastrointestinal	 discomfort,	 allergic	 reac-
tions,	myalgias,	edema,	erectile	dysfunction,	
and	neuropsychological	symptoms.	
Red-yeast rice is similar to placebo  
or another statin in statin-induced myalgia
In	a	small	community-based	trial	of	62	adults	
with	 dyslipidemia	 and	 a	 history	 of	 statin-
induced	 myalgia,	 investigators	 randomized	
patients	to	receive	either	red-yeast	rice	extract	
at	1800	mg	(with	3.1	mg	lovastatin)	or	place-
bo	 twice	daily	 for	24	weeks.4	Patients’	weekly	
self-reports	of	pain	(on	a	10-point	scale)	were	
skewed	 at	 baseline	 (1.4	 in	 the	 red-yeast	 rice	
group	vs	2.6	in	the	placebo	group;	P=.026)	but	
similar	at	12	weeks	(1.4	with	red-yeast	rice	vs	
1.9	with	placebo;	P=.30)	and	24	weeks	(1.2	with	
red-yeast	rice	vs	2.0	with	placebo;	P=.120).	
An	 RCT	 of	 43	 adults	 with	 dyslipidemia	
and	 history	 of	 statin	 intolerance	 compared	
red-yeast	 rice	 extract	 (2400	mg,	with	 10	mg	
lovastatin)	 with	 pravastatin	 (20	 mg)	 dosed	
twice	 a	 day.5	At	 the	 end	 of	 12	 weeks,	mean	
self-reported	 pain	 scores	 (on	 a	 10-point	
scale)	were	similar	(1.4	with	red-yeast	rice	vs	
1.1	with	pravastatin;	P=.82),	as	were	discon-
tinuation	 rates	because	of	myalgia	 (5%	with	
red-yeast	rice	vs	9%	with	pravastatin;	P=.99).
Recommendations 
A	 narrative	 review	 of	 alternative	 therapies	
for	 heart	 failure	 and	 hypercholesterolemia	
states	that	red	yeast	rice	may	be	a	cost-saving	
option	 for	 hypercholesterolemia	 in	 patients	
who	 can’t	 afford	 other	 medications	 (pur-
chased	mostly	online,	cost	$8-$20/month	for	
a	dosage	equivalent	to	lovastatin	20	mg/d).6	
A	ConsumerLab	review	of	red	yeast	rice	
products	 available	 since	 the	 FDA	 ban	 in	
2011	tested	products	marketed	in	the	United	
States	and	 found	variable	amounts	of	 lovas-
tatin.1,7	The	 group	 determined	 that	 labeling	
was	a	poor	guide	to	lovastatin	content,	which	
ranged	 from	0	 to	 20	mg	per	daily	dose,	 and	
that	 the	 products	 may	 not	 have	 been	 stan-
dardized.	 The	 group	 concluded	 that	 thera-
peutic	effects	weren’t	predictable.		 														JFP
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